Trafficking of granulocytes, CFU-GMs, and HSCs in spleen, marrow, and blood of parabiotic mice at baseline and after cytokine or AMD3100 mobilization
Mobilization regimen*†, tissue, and wk of parabiosis . | No. pairs . | Mean % partner granulocytes ± SD‡ . | Mean % partner CFU-GMs ± SD‡ . | Mean % partner HSCs ± SD‡§ . |
|---|---|---|---|---|
| No mobilization | ||||
| Spleen | ||||
| 3 | 3 | 43.3 ± 10.0 | 46.0 ± 11.4 | 2.4 ± 2.4 |
| 6 | 2 | 38.0 ± 11.2 | 47.2 ± 2.5 | 1.5 ± 1.3 |
| Marrow | ||||
| 3 | 3 | 2.3 ± 0.6 | 2.4 ± 0.4 | 1.0 ± 0.8 |
| 6 | 3 | 2.9 ± 0.1 | 3.5 ± 1.4 | 1.4 ± 0.4 |
| Blood | ||||
| 3 | 6 | 39.3 ± 9.3 | 42.1 ± 7.7 | NR |
| 6 | 1 | 41.8 ± 6.6 | 41.8 ± 4.8 | NR |
| G + S | ||||
| 1 mobilization cycle | ||||
| Spleen | ||||
| 3 | 3 | NA | NA | NA |
| 6 | 4 | NA | NA | NA |
| Marrow | ||||
| 3 | 3 | 5.9 ± 3.9 | 6.1 ± 4.4 | 2.9 ± 1.1|| |
| 6 | 4 | 10.9 ± 6.2 | 9.8 ± 5.4 | 10.1 ± 6.2|| |
| Blood | ||||
| 3 | 3 | 40.9 ± 4.3 | 46.3 ± 11.1 | 25.4 ± 8.6 |
| 6 | 4 | 38.1 ± 11.8 | NA | 1.5 ± 0.9 |
| 3 mobilization cycles | ||||
| Spleen | ||||
| 5 | 3 | 49.3 ± 6.7 | 46.5 ± 11.7 | 35.8 ± 8.8|| |
| 6 | 3 | 48.6 ± 4.7 | 49.0 ± 7.8 | 24.1 ± 18.0|| |
| Marrow | ||||
| 5 | 3 | 16.4 ± 4.1 | 17.6 ± 4.7 | 18.1 ± 10.6|| |
| 6 | 3 | 18.7 ± 9.1 | 20.7 ± 9.7 | 13.4 ± 9.9|| |
| Blood | ||||
| 5 | 3 | 49.9 ± 6.8 | 49.5 ± 10.9 | 45.9 ± 30.0 |
| 6 | 3 | 38.9 ± 7.2 | 41.7 ± 6.0 | 21.4 ± 18.0 |
| AMD3100 | ||||
| 1 mobilization cycle | ||||
| Spleen | ||||
| 6 | 3 | 40.0 ± 6.1 | 44.0 ± 3.2 | 6.8 ± 2.3|| |
| Marrow | ||||
| 6 | 3 | 5.6 ± 2.8 | 5.7 ± 2.3 | 5.5 ± 2.3|| |
| Blood | ||||
| 6 | 3 | 46.9 ± 9.3 | 46.0 ± 5.1 | 5.3 ± 2.1 |
Mobilization regimen*†, tissue, and wk of parabiosis . | No. pairs . | Mean % partner granulocytes ± SD‡ . | Mean % partner CFU-GMs ± SD‡ . | Mean % partner HSCs ± SD‡§ . |
|---|---|---|---|---|
| No mobilization | ||||
| Spleen | ||||
| 3 | 3 | 43.3 ± 10.0 | 46.0 ± 11.4 | 2.4 ± 2.4 |
| 6 | 2 | 38.0 ± 11.2 | 47.2 ± 2.5 | 1.5 ± 1.3 |
| Marrow | ||||
| 3 | 3 | 2.3 ± 0.6 | 2.4 ± 0.4 | 1.0 ± 0.8 |
| 6 | 3 | 2.9 ± 0.1 | 3.5 ± 1.4 | 1.4 ± 0.4 |
| Blood | ||||
| 3 | 6 | 39.3 ± 9.3 | 42.1 ± 7.7 | NR |
| 6 | 1 | 41.8 ± 6.6 | 41.8 ± 4.8 | NR |
| G + S | ||||
| 1 mobilization cycle | ||||
| Spleen | ||||
| 3 | 3 | NA | NA | NA |
| 6 | 4 | NA | NA | NA |
| Marrow | ||||
| 3 | 3 | 5.9 ± 3.9 | 6.1 ± 4.4 | 2.9 ± 1.1|| |
| 6 | 4 | 10.9 ± 6.2 | 9.8 ± 5.4 | 10.1 ± 6.2|| |
| Blood | ||||
| 3 | 3 | 40.9 ± 4.3 | 46.3 ± 11.1 | 25.4 ± 8.6 |
| 6 | 4 | 38.1 ± 11.8 | NA | 1.5 ± 0.9 |
| 3 mobilization cycles | ||||
| Spleen | ||||
| 5 | 3 | 49.3 ± 6.7 | 46.5 ± 11.7 | 35.8 ± 8.8|| |
| 6 | 3 | 48.6 ± 4.7 | 49.0 ± 7.8 | 24.1 ± 18.0|| |
| Marrow | ||||
| 5 | 3 | 16.4 ± 4.1 | 17.6 ± 4.7 | 18.1 ± 10.6|| |
| 6 | 3 | 18.7 ± 9.1 | 20.7 ± 9.7 | 13.4 ± 9.9|| |
| Blood | ||||
| 5 | 3 | 49.9 ± 6.8 | 49.5 ± 10.9 | 45.9 ± 30.0 |
| 6 | 3 | 38.9 ± 7.2 | 41.7 ± 6.0 | 21.4 ± 18.0 |
| AMD3100 | ||||
| 1 mobilization cycle | ||||
| Spleen | ||||
| 6 | 3 | 40.0 ± 6.1 | 44.0 ± 3.2 | 6.8 ± 2.3|| |
| Marrow | ||||
| 6 | 3 | 5.6 ± 2.8 | 5.7 ± 2.3 | 5.5 ± 2.3|| |
| Blood | ||||
| 6 | 3 | 46.9 ± 9.3 | 46.0 ± 5.1 | 5.3 ± 2.1 |
NR indicates no reconstitution of irradiated recipients; NA, not available.
Mice received G-CSF and SCF (G + S) subcutaneously on days 17 to 20 (1 cycle of mobilization) or on days 17 to 20, days 24 to 27 and days 31 to 34 of parabiosis (3 cycles of mobilization). Phenotypes of HSCs in marrow and blood were assessed 1 day or 1 week after cytokine administration (ie, after 5 or 6 weeks of parabiosis, respectively)
Mice received AMD3100 (5 mg/kg) subcutaneously on day 21 of parabiosis. Phenotypes of HSCs in marrow and blood were assessed 3 weeks after AMD3100 administration (ie, at 6 weeks of parabiosis)
The percent of partner granulocytes, CFU-GMs, and HSCs represent data averaged from the parabiotic pairs
HSC engraftment was defined by granulocytic chimerism. HSC engraftment defined by lymphoid chimerism was always equivalent (data not shown)
P ≤ .05 compared with respective control (no mobilization) mice